Top Page
Vitasora Health
(OTC:VHL)
Vitasora Health (VHL) vs. iShares MSCI Australia ETF (EWA)
Vitasora Health Business Overview & Revenue Model
Vitasora Health Financial Statement Overview
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
Vitasora Health Technical Analysis
Vitasora Health Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$67.92M | -49.28 | -6.35% | ― | 2.23% | -263.16% | |
49 Neutral | AU$49.85M | -4.64 | -44.16% | ― | 25.47% | 14.08% | |
48 Neutral | $69.30M | -2.96 | -74.00% | ― | 23.31% | -17.35% | |
44 Neutral | AU$171.01M | -15.78 | -70.55% | ― | ― | -257.32% | |
41 Neutral | AU$42.74M | -3.19 | -114.43% | ― | 580.63% | -2.86% | |
41 Neutral | AU$60.80M | -3.81 | -128.19% | ― | -14.25% | -22.83% |
Vitasora Health Corporate Events
Vitasora Health Limited has announced the lapse of 18.5 million unexercised options (ASX code VHLAAD) that were due to expire on January 1, 2026, each with an exercise price of A$0.10. The expiry of these options without conversion reduces the company’s potential future dilution from this specific class of securities, marginally simplifying its capital structure and clarifying issued capital for existing and prospective shareholders.
Vitasora Health Limited has disclosed a change in director Marjan Mikel’s interests in the company’s securities, as required under ASX listing rules. The filing shows that 30,000,000 options previously held indirectly through related entities have lapsed on their expiry date without consideration, leaving Mikel’s direct and remaining indirect shareholdings unchanged; the adjustment is administrative in nature but clarifies his current equity exposure for investors and the market.
Vitasora Health Limited has announced the issuance of 118,633,332 fully paid ordinary shares, raising AU$3.559 million from a cornerstone investor, with an additional AU$3.191 million expected by December 22, 2025. This financial move is part of their ongoing efforts to strengthen their market position and expand their innovative healthcare solutions, which are designed to improve patient care and reduce costs. The issuance was conducted without disclosure under specific provisions of the Corporations Act, and the company has complied with all necessary regulations, ensuring transparency and compliance with investor information requirements.
Vitasora Health Limited has announced the quotation of 118,633,332 fully paid ordinary securities on the Australian Securities Exchange as of December 1, 2025. This move is part of a previously announced transaction, potentially enhancing the company’s market presence and providing additional liquidity for stakeholders.
Vitasora Health Limited announced the successful passing of all resolutions at their annual general meeting, signaling strong shareholder support for their strategic direction. This development reinforces Vitasora’s position as a leader in digital healthcare solutions, particularly in chronic disease management, and is likely to enhance their operational capabilities and stakeholder confidence.
Vitasora Health Limited announced an amendment to its previously lodged Appendix 2A, correcting the number of shares issued to 5,116,667 due to an administrative error. This amendment does not affect the Section 708A Cleansing Notice lodged earlier. The announcement underscores Vitasora’s commitment to transparency and accuracy in its financial reporting, which is crucial for maintaining investor trust and confidence.
Vitasora Health Limited has issued 6.7 million fully paid ordinary shares, as announced in their recent ASX release. This move aligns with their strategic efforts to enhance their market presence and operational capabilities in the healthcare sector, particularly in the U.S. market. The company’s focus on integrating advanced solutions into existing healthcare systems aims to boost efficiency and reduce costs, further solidifying their position as a leader in chronic disease management.
Vitasora Health Limited has announced the issuance of 6,700,000 ordinary fully paid shares to contractors as compensation for services rendered to the company. This move is part of the company’s strategy to strengthen its operational capabilities and enhance its market position by leveraging external expertise.
Vitasora Health Limited reported significant growth in patient programs and revenue for the quarter ending September 2025. The company expanded its partnerships, notably with Tampa Family Health Centers and Iris Medical Group, to include new services and increase patient enrolments. This expansion is expected to drive substantial revenue growth in the upcoming quarter. Vitasora’s operational expansion and application of AI-driven automation have improved scalability and performance, contributing to a 160% year-on-year revenue increase. The company also strengthened its capital position, ensuring funding through to cash-flow breakeven by Q4 FY2026.
Vitasora Health Limited has announced an expansion of its services to include Evolent’s rural markets, following the success of its Hawaii pilot program. This expansion is expected to generate an annualized recurring revenue of US$12-US$18 million by targeting 20,000-30,000 patients in 2026 under the Medicare MSSP and Medicare FFS models. The divestiture of Evolent Care Partners to Privia Health Group provides Vitasora with a larger platform to scale its services across multiple states, offering significant revenue opportunities and a pathway to profitability. The integration with Privia Health, which manages approximately 1.5 million lives, represents a major growth opportunity for Vitasora, affirming its position as a partner with leading value-based care organizations.
Vitasora Health Limited has successfully received AU$2.43 million from a cornerstone investor as part of a larger AU$6.75 million commitment, which is crucial for completing their AU$11 million capital raise. This funding will support Vitasora’s operational growth and help achieve cash-flow breakeven by Q4 FY2026. The company is expanding its U.S. operations through partnerships, such as with Tampa Family Medical Centers and Iris Healthcare, and is in advanced negotiations for additional contracts. These developments underscore Vitasora’s strong market position and the confidence of investors in its Connected Care model, which is expected to drive sustainable growth and profitability.
Vitasora Health Limited has announced that its 2025 Annual General Meeting will be held virtually on November 19, 2025. Shareholders are encouraged to vote by proxy and can participate in the meeting online, where they will have the opportunity to ask questions and vote on resolutions. This move to a virtual format aligns with modern practices and ensures broader accessibility for stakeholders, potentially enhancing shareholder engagement and operational transparency.
Vitasora Health Limited has announced its Annual General Meeting, which will be held virtually on November 19, 2025. Shareholders are encouraged to submit proxies early and can participate in the meeting online, where they will have the opportunity to ask questions and vote on proposed resolutions. The company has made the meeting details and related documents available on its website, emphasizing the importance of reviewing these materials thoroughly.